Cellectis (CLLS) Q2 2026 earnings review
Clinical Wins Overshadowed by Collapsing Partner Revenue
Cellectis is showing strong clinical momentum, highlighted by an FDA RMAT designation for lasme-cel and a 100% overall response rate in its Phase 2 target population. However, the financial picture is rapidly deteriorating. Q2 revenue collapsed 69% YoY to just $5.2M as AstraZeneca collaboration activities stalled. Consequently, the H1 operating loss doubled to $48.7M. While management touts a stable net loss, this is an accounting mirage driven entirely by non-cash fair value gains on EIB warrants and foreign exchange. The cash runway remains intact into late 2027, but the core business burn rate is accelerating.
🐂 Bull Case
Lasme-cel is showing a 100% ORR (7/7) and 57% CR/CRi in its target Phase 2 population for heavily pretreated B-ALL. The FDA's RMAT designation structurally de-risks the regulatory pathway.
With $169 million in cash and fixed-term deposits, Cellectis has secured runway into Q4 2027, successfully bridging the gap to crucial pivotal data readouts for both lasme-cel and eti-cel.
🐻 Bear Case
Total H1 revenues plummeted by $15.8M (down 52%), driven directly by a lower level of research activities performed under the AstraZeneca Joint Research Collaboration Agreement. If this pipeline engine slows permanently, Cellectis loses its primary cash-generation mechanism.
The company reported a virtually flat YoY net loss (-$21.8M vs -$23.7M). However, operating losses actually widened by 145% YoY in Q2. The bottom line was artificially rescued by a $6.5M non-cash gain on EIB warrants.
⚖️ Verdict: ⚪
Neutral. The pipeline technology is undeniably potent, with pristine response rates and favorable safety profiles. However, the sudden deceleration in AstraZeneca partnership revenues and the masked blowout in operating expenses demand strict investor caution.
Key Themes
Lasme-cel RMAT Validates Differentiated Approach
Securing FDA Regenerative Medicine Advanced Therapy (RMAT) designation for lasme-cel is a massive fundamental driver. Efficacy is flawless in the target Phase 2 group (100% ORR), and importantly, safety is highly manageable (only 4% Grade 3+ CRS/ICANS). All responding patients successfully bridged to hematopoietic stem cell transplantation (HSCT), proving the therapy's real-world utility as a definitive consolidation tool.
AstraZeneca Partnership Revenue Decelerating
Revenue trends are severely reversing. First-half consolidated revenues dropped from $30.2M in 2025 to $14.5M in 2026. Management explicitly blamed the 'level of activities performed under the Research Plans' of the AZ agreement. Given this agreement was the central bullish thesis for near-term cash flow, any pause in AZ's commitment to the 10 novel targets is a severe red flag.
Operating Burn Accelerates as Clinical Costs Mount
Despite management presenting a flat net loss, H1 R&D expenses jumped 16% to $52.2M, driven by higher clinical development costs for BALLI-01 and NATHALI-01. This contradicts the positive 'steady cash burn' narrative; the company is burning more cash from operations, but masking it on the income statement via fair value adjustments on EIB warrants and FX fluctuations.
Eti-cel Offers Post-CD19 Salvage Option
Eti-cel is proving to be a highly viable non-CD19 alternative. With 93% of the NATHALI-01 cohort having previously failed CD19 CAR-T, achieving an 88% ORR and 63% CR rate demonstrates the power of targeting CD20/CD22. This positions eti-cel perfectly as an off-the-shelf salvage therapy for the growing population of patients who relapse after autologous CD19 treatments.
Translational Data Driving Protocol Innovations
Cellectis is aggressively iterating on clinical protocols based on real-time data. High alemtuzumab exposure was linked to enhanced eti-cel expansion and better responses. Consequently, the company is shifting to a weight-based alemtuzumab dosing regimen for optimized lymphodepletion. Additionally, they are evaluating subcutaneous low-dose IL-2 to further drive cell expansion, showcasing an agile, science-first development approach.
Mounting Legal and IP Distractions
While not explicitly detailed in the Q2 press release, previous filings note rising legal friction, including Factor Bioscience's patent infringement suit (Sept 2025) and Life Technologies Corporation moving to terminate 2014 patent licenses (April 2026). These arbitration and litigation battles threaten to drain capital and management attention at exactly the moment pivotal execution is required.
Macro Impact: Foreign Exchange Volatility
Cellectis operates with immense exposure to USD/EUR currency pairs. In 2025, the company suffered massive FX losses due to USD devaluation against the Euro. In H1 2026, the trend reversed entirely, with the appreciation of the USD wiping out $22.8M in foreign exchange losses from the comparative period. This massive macro volatility severely distorts the company's true bottom-line performance.
Other KPIs
Accelerating. Up from $45.0M in H1 2025. This $7.2M jump was driven directly by higher clinical development costs related to the pivotal transition of the BALLI-01 and NATHALI-01 studies, as well as an increase in personnel and stock-based compensation expenses. As these trials expand geographically (e.g., UK MHRA approval), expect R&D to scale higher.
Declining. Cash balances fell by $42M from $211M at year-end 2025. The cash drain was driven by $26.9M in supplier payments and $28.5M in payroll, only partially offset by $16.8M in customer cash receipts. The company maintains its guidance that this balance provides runway into Q4 2027, essentially covering the critical pivotal readouts.
Guidance
Stable. The company remains on track to deliver the first interim analysis for the pivotal Phase 2 trial in the fourth quarter. This is the single most important value-inflection milestone for the stock.
Stable. Management confirmed they will present the full Phase 1 dataset, which will be critical to see how the weight-based alemtuzumab dosing and low-dose IL-2 combinations impact durability and expansion.
Stable. Despite higher operating burns in Q1 and Q2, management reiterated that current liquidity will fund operations into the fourth quarter of 2027, avoiding any immediate need for dilutive capital raises prior to Q4 2026 data readouts.
Key Questions
AstraZeneca Collaboration Dynamics
First-half revenue from collaboration agreements dropped by more than 50% year-over-year. Can you explicitly detail why the level of research activity under the AstraZeneca agreement has decelerated, and should we model this lower baseline run-rate going forward?
Operating Burn Trajectory
Operating losses doubled in the first half of 2026 compared to 2025. With Phase 2 enrollments accelerating across France, Italy, Spain, and the UK, what is the expected peak quarterly cash burn rate as we move through late 2026?
Alemtuzumab Sourcing and Field Perception
With the shift toward weight-based alemtuzumab dosing in NATHALI-01, how do you expect regulators and the broader market to interpret your continued reliance on CD52 lymphodepletion, especially after peers have completely abandoned their proprietary CD52 antibodies?